Lantern Pharma Inc.

8-K · form8-k.htm

0001763950

 2026-06-01
 2026-06-01

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

  

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

  

 FORM
 8-K

  

 CURRENT
REPORT

 Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

  

 Date
of Report (Date of earliest event reported): June 1, 2026

  

 Lantern
Pharma Inc.

 (Exact
name of registrant as specified in its charter)

  

 Delaware
  
 001-39318
  
 46-3973463

 (State
 or Other Jurisdiction

 of
 Incorporation)

  
 (Commission

 File
 Number)

  
 (IRS
 Employer

 Identification
 No.)

  

 1920
 McKinney Avenue , 7th Floor

 Dallas ,
 Texas

  
 75201

 (Address
 of Principal Executive Offices)
  
 (Zip
 Code)

  

 (972)
 277-1136

 (Registrant’s
telephone number, including area code)

  

 Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

  

 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
  

 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  

 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
  

 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities
registered pursuant to Section 12(b) of the Act: Common Stock

  

 Title
 of each class
  
 Trading
 Symbol
  
 Name
 of each exchange on which registered

 Common
 Stock, $0.0001 par value
  
 LTRN
  
 The
 Nasdaq Stock Market

  

 Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging
growth company ☐

  

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item
7.01 Regulation FD Disclosure.

  

 On
June 1, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s discussions
regarding the Harmonic™ Phase 2 clinical trial for the Company’s product candidate known as LP-300.

  

 A
copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

  

 The
information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

  

 Item
9.01 Financial Statements and Exhibits.

  

 (d)
 Exhibits .

  

 Exhibit
 No.
  
 Exhibit
 Description

  
  
  

 99.1
  
 Presentation relating to June 1, 2026 discussions regarding the Harmonic™ LP-300 Phase 2 clinical trial.

 104
  
 Cover
 Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

  

 2

  

  

 SIGNATURES

  

 Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  

  
 Lantern
 Pharma Inc.,

  
 A
 Delaware Corporation

  
  
  

 Dated:
 June 1, 2026
 By:
 /s/
 David R. Margrave

  
  
 David
 R. Margrave, Chief Financial Officer

  

 3